Abstract Metformin, one of the most widely prescribed antidiabetic drugs in the world, is being repurposed as a potential drug in cancer treatment. Epidemiological studies suggest that metformin exerts anticancer effects in diabetic patients with pancreatic cancer. However, at typical antidiabetic doses the bioavailability of metformin is presumably too low to exert antitumor effects. Thus, more potent analogs of metformin are needed in order to increase its anticancer efficacy. To this end, a new class of mitochondria-targeted metformin analogs (or mito-metformins) containing a positively-charged lipophilic triphenylphosphonium group was synthesized and tested for their antitumor efficacy in pancreatic cancer cells. Results indicate that the lead compound, mito-metformin 10 , was nearly 1000-fold more potent than metformin in inhibiting mitochondrial complex I activity, inducing reactive oxygen species (superoxide and hydrogen peroxide) that stimulate redox signaling mechanisms, including the activation of adenosinemonophosphate kinase and inhibition of proliferation of pancreatic cancer cells. The potential use of the low-temperature electron paramagnetic resonance technique in assessing the role of mitochondrial complexes including complex I in tumor regression in response to metformin and mito-metformins in the in vivo setting is discussed.
Introduction
Metformin (Met, Fig. 1 ) is one of the most prescribed antidiabetic drugs in the world [1, 2] . Metformin is a derivative of guanidine, an active component in the extracts from French lilac (G. officinalis), the plant that has been Fig. 1 Chemical structures of metformin and mito-metformin analogs used for centuries to combat diabetes. A major advantage of metformin as a drug is that it is relatively safe and diabetic patients typically take daily several grams of the drug. Recently metformin is being repurposed as an antitumor drug due to epidemiological findings, revealing an association between decreased incidence of pancreatic cancer and metformin use in diabetic individuals [3, 4] . However, at typical antidiabetic doses, the bioavailability of metformin and/or its uptake by cancer cells is probably too low to exert its antitumor effects in humans, although singificant antitumor activity was reported in the rodent models, at comparable plasma concentrations [5, 6] . It appears that the antineoplastic activity of metformin in humans will require much higher concentrations of the drug in the serum than what is typically administered in diabetics treated with metformin [5] . Thus, it is important to develop new and improved metformin analogs with increased bioavailability, resulting in more potent antitumor effects, although these analogs may show increased toxicity for routine treatment of diabetes. We hypothesized that attaching the triphenylphosphonium cation (TPP + ) to metformin via an alkyl chain would greatly enhance its accumulation in mitochondria of cancer cells, leading to selective inhibition of proliferation of cancer cells [7] . Results obtained in this study substantiate the proposal that TPP + -modified metformins are more cytostatic to pancreatic cancer cells. Metformin does not undergo metabolism like many other drugs but it is excreted out unchanged in the urine [8] . However, it induces extensive changes in the metabolic pathways and mitochondrial energy metabolism [9] . Although multiple mechanisms were proposed for metformin anticancer effects, mitochondria still remain as the major target of metformin, leading to inhibition of cell respiration, adenosine monophosphate (AMP)-activated protein kinase (AMPK) activation, mTOR inhibition, and inhibition of cell proliferation [10, 11] .
Recent research implicates a role for mitochondrial complex I inhibition in the antitumor effects of metformin [12] . Interestingly, cancers with mutations in mitochondrial genes encoding proteins of the mitochondrial complex I of the electron transport chain are more susceptible to biguanides such as metformin [13] . Thus, cancers with oxidative phosphorylation deficits are likely to be more sensitive to biguanides than normal tissues and, consequently, patients with complex I mutated cancer phenotype may be more sensitive to metformin treatment [14] . Tumor microenvironment was proposed to be another factor for increased metformin potency in some tumor phenotypes [15] . More recently, metformin was reported to activate T cell-mediated immune response against cancer cells [15] [16] [17] .
We have recently shown that attaching a positivelycharged lipophilic triphenylphosphonium group to a nitroxide, quinone, or a phenolic group via an aliphatic linker chain vastly enhanced their ability to target mitochondria, and that such mitochondria-targeted compounds (e.g., Mito-CP, Mito-Q and Mito-Vitamin-E) significantly induced antiproliferative and/or cytotoxic effects in tumor cells without markedly affecting noncancerous cells [18] [19] [20] [21] [22] [23] . Similarly, we hypothesized that attaching a positivelycharged lipophilic substituent will improve mitochondrial targeting of metformin (e.g., mito-metformins, Fig. 1 ), thereby generating a new class of metformin analogs with enhanced antitumor potential. Results show that the mitometformin analogs are much more potent (100-1000-fold higher) than metformin in inhibiting human pancreatic adenocarcinoma cells (PDACs) [7] .
Antiproliferative Effects of Metformin and MitoMetformin 10
The effect of mito-metformin 10 and metformin on MiaPaCa-2 cells was investigated by monitoring colony formation and cell proliferation. As shown in Fig. 2 , in order to inhibit proliferation of pancreatic cancer cells, metformin was used at millimolar levels, whereas mitometformin 10 was used at micromolar concentrations. The IC 50 values for inhibition of proliferation of human pancreatic cancer cells (MiaPaCa-2 and PANC-1) were more than 1000-fold lower for Mito-Met 10 (0.2 µM), as compared to Met (0.6-0.9 mM). MiaPaCa-2 cells which were treated with 0.5 or 1 mM concentration of metformin, or 0.5-1 µM concentration of mito-metformin, showed the same effects in colony formation and cell proliferation experiments [7] . The IC 50 values for inhibiting 50% of colony formation for metformin and mito-metformin 10 were calculated to be 1.3 mM and 1.1 µM, respectively. Thus, mito-metformin 10 is ca. 1000-fold more effective than metformin. The colony forming ability of the pancreatic cancers cells, while decreased by treatment with Mito-Met 10 , could be rescued be cell pre-treatment with compound C, an inhibitor of AMPK protein (Fig. 2b) . This indicates that AMPK signaling pathway is involved in the antiproliferative effects of Mito-Met 10 . Interestingly, Mito-Met 10 showed a good selectivity towards pancreatic cancer cells, as compared to non-tumorigenic cells (Fig. 2a) , implicating a wider margin of therapeutic index for its use in vivo.
Inhibition of Pancreatic Cancer Cell Respiration: Complex I Involvement
Metformin is weakly cationic, and weakly targets mitochondria. Metformin's antitumor effects were attributed in part to its ability to inhibit mitochondrial complex Idependent cell respiration and ATP generation [7, 12] . In contrast to rotenone, a non-selective inhibitor of complex I in both normal and cancer cells, metformin reversibly and more selectively inhibits mitochondrial complex I in cancer cells [12] . As mito-metformin 10 selectively accumulates into mitochondria, we compared the relative inhibitory effects of metformin and mito-metformin 10 on complex I activity in MiaPaCa-2 cells. The real time monitoring of oxygen consumption rate (OCR) was used as a measure of mitochondrial function in intact cells. The mitochondrial respiration or OCR was monitored in MiaPaCa-2 cells treated with metformin and mito-metformin 10 using the Seahorse XF extracellular flux analyzer [7] . Figure 3 shows the OCR measurement of mitochondrial complex I activity of MiaPaCa-2 cells pretreated for 24 h with metformin or mito-metformin 10 . The IC 50 values for inhibition of mitochondrial complex I for metformin and mito-metformin 10 were determined to be ca. 1.1 mM and 0.4 µM. These results show that the complex I inhibition may be mechanistically related to the antiproliferative effects of these compounds. Again, Mito-Met 10 exhibited selectivity towards cancer cells in inhibiting mitochondrial complex I (Fig. 3) .
Mito-Metformin-Mediated Stimulation of Reactive Oxygen Species (ROS) and Redox Signaling
One of the consequences of inhibiting mitochondrial complex I is stimulation of one-electron reduction of oxygen to superoxide radical anion (O 2
•-) and other oxidants (hydrogen peroxide and higher oxidation heme species) derived from superoxide [7] . As mito-metformin 10 treatment (at the concentration inhibiting proliferation) did not exert any cytotoxic effects, it is likely that ROS generated from mitochondria could be involved in redox signaling [7] . We used the cell-permeable probe, hydroethidine (HE), to detect superoxide by monitoring 2-OH-E + , the specific marker product of the reaction between superoxide and HE [24] [25] [26] . A marked increase in 2-OH-E + formation was observed in mito-metformin 10 -treated MiaPaCa-2 cells (Fig. 4) . Evidence for other one-electron oxidation species formed from mito-metformin 10 interaction with mitochondrial proteins arose from studies demonstrating the formation of ethidium and a dimeric product of HE (E + and E + -E + , Fig. 4 ) in isolated mitochondria and upon incubation of HE with heme proteins [27, 28] . Under similar experimental conditions, mito-metformin 10 did not stimulate superoxide formation in non-cancerous human pancreatic epithelial renin-expressing (HPNE) cells (Fig. 4) . We used the probe o-MitoPhB(OH) 2 to detect H 2 O 2 generated in mito-metformin-treated cells [29] [30] [31] . Results show that mito-metformin 10 treatment of MiaPaCa-2 cells in the presence of o-MitoPhB(OH) 2 led to an increase in oMitoPhOH formation (Fig. 5) . Although this product can be formed from either H 2 O 2 , peroxynitrite, or hypochlorous acid reaction with o-MitoPhB(OH) 2 , the lack of detection of peroxynitrite-or hypochlorous acid-specific products in addition to o-MitoPhOH suggests that H 2 O 2 was responsible for oxidation of o-MitoPhB(OH) 2 to MitoPhOH [29] [30] [31] .
Mito-metformin 10 activated AMPK phosphorylation at a 1000-fold lower concentration than metformin [7] . AMPK is a master regulator of cellular energy homeostasis and is activated via phosphorylation of its threonine-172 residue [32] . AMPK activation was linked to increased formation of hydrogen peroxide [33, 34] . Based on the results showing that mito-metformin 10 stimulated mitochondrial superoxide, hydrogen peroxide and AMPK activation, we proposed that mito-metformin 10 -mediated antiproliferative effects are linked to inhibition of mitochondrial complex, enhanced ROS formation and AMPK phosphorylation (Fig. 6 ). These observations have been recently confirmed by an independent study on antiproliferative effects of triphenylphosphonium-linked metformin derivatives against pancreatic cancer cells [35] .
Potential use of Ex Vivo Low-Temperature EPR in Elucidating Mitochondrial Mechanism
Whereas the Seahorse technique can be used to measure the activities of mitochondrial complexes in cells, it is challenging to use this technique to measure mitochondrial activities in tissues. The low-temperature electron paramagnetic Fig. 3 Effects of metformin and mito-metformin 10 on mitochondrial complex I activity in pancreatic cancer (MiaPaCa-2 and PANC-1) and non-tumorigenic (HPNE and IEC-6) cells [7] resonance (EPR) spectroscopy is uniquely capable of providing a "snapshot" of mitochondrial status in intact tissues [36] . To our knowledge, the EPR technique has not been used to monitor changes in the redox status of mitochondrial iron-sulfur complexes in cancer cells. The effect of mitometformin 10 and metformin on complex I activity in tumor tissues can be determined by performing EPR measurements at liquid helium temperatures. The signal at g = 1.94 attributable to the reduced form of [2Fe-2S]
+ center of mitochondrial complex I is monitored [36, 37] . Inhibition of this signal is equated to inhibition of complex I. In a recent publication, Bennett et al. discussed the use of lowtemperature EPR in mitochondrial diseases [38] . ROS generated from inhibiting complex I will react with other iron sulfur-containing proteins (e.g., mitochondrial and cytosolic aconitases), and the levels of oxidativelyinactivated aconitases can be monitored at g = 2.03 and
EPR signals due to the [3Fe-4S]
+ form of aconitase [37, 39] . Oxidatively-inactivated mitochondrial aconitase has a distinctly different EPR signal from oxidativelyinactivated cytosolic aconitase [37, 39] . Other signals from reduced and oxidized iron sulfur centers associated with downstream complexes I and II in the electron transport chain are also detectable using the low-temperature EPR. These experiments can be done in both preclinical and human tumor samples, and may provide additional mechanistic insights into response to therapy.
Conclusions
We have demonstrated that more potent analogs of metformin (a.k.a. mito-metformins) can be synthesized by attaching a mitochondria-targeting triphenylphosphonium group tethered to an alkyl side chain. Mito-metformin 10 was determined to be the most potent analog tested in inhibiting mitochondrial respiration, ROS activation, AMPK phosphorylation, and inhibition of proliferation in pancreatic cancer cells. We propose that AMPK activation induced by complex I-mediated ROS signaling is responsible for the antiproliferative effects. More recently, hydrogen peroxide was reported to induce redox signaling via a redox-relay involving peroxiredoxins and STAT3 [40] . One of the major targets of mito-metformins is the mitochondrial complex I in the electron transport chain. The exact mechanism by which metformin analogs inhibit complex I
is not yet ascertained. It has been reported that the occurrence of mitochondrial complex I A/D transition could regulate ROS production [41] . The D-form of the enzyme has been shown to generate more O 2 •-than the A-form, and irreversible locking of complex I in the D-form may contribute to more O 2 •-formation [41] . Establishing this mechanism in the in vivo preclinical pancreatic cancer xenografts may be accomplished using the low-temperature EPR technique. This ex vivo EPR technique may also be extrapolated to analysis of human pancreatic tumors. 
